

DAFTAR PUSTAKA

- Apri, S., & Desi, Y. M. A., 2015, Faktor-Faktor Determinat Terjadinya Kanker Ovarium Di Rumah Sakit Umum Daerah Abdoel Mpelok Provinsi Lampung 2015, P- Issn: 2086-3071, E-Issn: 7(2), 79–87.
- Atallah Ga, Abd Aziz Nh, Teik Ck, Shafiee Mn, Kampan Nc. New Predictive Biomarkers For Ovarian Cancer. *Diagnostics (Basel)*. 2021 Mar 7;11(3):465. Doi: 10.3390/Diagnostics11030465. Pmid: 33800113; Pmcid: Pmc7998656.
- Bambace Nm, Holmes Ce. The Platelet Contribution To Cancer Progression. *J Thromb Haemost*. 2011 Feb;9(2):237-49. Doi: 10.1111/J.1538-7836.2010.04131.X. Pmid: 20340448.
- Bamias, A., Sotiropoulou, M., Zagouri, F., Trachana, P., Sakellariou, K., Kostouros, E., Kakoyianni, K., Rodolakis, A., Vlahos, G., Haidopoulos, D., Thomakos, N., Antsaklis, A., Dimopoulos, M.A., 2012. Prognostic Evaluation Of Tumour Type And Other Histopathological Characteristics In Advanced Epithelial Ovarian Cancer, Treated With Surgery And Paclitaxel/Carboplatin Chemotherapy: Cell Type Is The Most Useful Prognostic Factor. *Eur J Cancer* 48, 1476–1483.
- Bednarska K, Król E, Głowacka E, Romanowicz H, Szyłło K, Klink M, Sułowska Z, Nowak M. Analysis Of Preoperative Blood Platelet Parameters In Terms Of Diversity Of Epithelial Ovarian Cancer. *Medicine (Baltimore)*. 2018 Mar;97(12):E0180. Doi: 10.1097/Md.00000000000010180. Erratum In: *Medicine (Baltimore)*. 2018 May;97(20):E10835. Pmid: 29561432; Pmcid: Pmc5895358.
- Berek, J. S., Crum, C., & Friedlander, M., 2015, Cancer Of The Ovary, Fallopian Tube, And Peritoneum. *International Journal Of Gynecology And Obstetrics*, 131, S111–S122. <https://doi.org/10.1016/J.Ijgo.2015.06.007>.
- Bonneau, C., Rouzier, R., Geyl, C., Cortez, A., Castela, M., Lis, R., Et Al., 2015. Predictive Markers Of Chemoresistance In Advanced Stages Epithelial Ovarian Carcinoma. *Gynecol. Oncol.* 136: 112–120. Doi:10.1016/J.Ygyno.2014.10.024
- Bookman, M.A., Brady, M.F., Mcguire, W.P., Harper, P.G., Alberts, D.S., Friedlander, M., Colombo, N., Fowler, J.M., Argenta, P.A., De Geest, K., Mutch, D.G., Burger, R.A., Swart, A.M., Trimble, E.L., Accario-Winslow, C., Roth, L.M., 2009. Evaluation Of New Platinum-Based Treatment Regimens In Advanced-Stage Ovarian Cancer: A Phase Iii Trial Of The Gynecologic Cancer Intergroup. *Journal Of Clinical Oncology* 27, 1419–1425. <https://doi.org/10.1200/Jco.2008.19.1684>
- Chang, L.-C., Huang, C.-F., Lai, M.-S., Shen, L.-J., Wu, F.-L.L., Cheng, W.-F., 2018. Prognostic Factors In Epithelial Ovarian Cancer: A Population-Based Study. *Plos One* 13, E0194993. <https://doi.org/10.1371/journal.pone.0194993>.

- Charkhchi P, Cybulski C, Gronwald J, Wong Fo, Narod Sa, Akbari Mr. Ca125 And Ovarian Cancer: A Comprehensive Review. *Cancers*. 2020; 12(12):3730. <https://doi.org/10.3390/Cancers12123730>
- Chase, D.M., Mahajan, A., Scott, D.A., Hawkins, N., Kalilani, L., 2023. Correlation Between Progression-Free Survival And Overall Survival In Patients With Ovarian Cancer After Cytoreductive Surgery: A Systematic Literature Review. *International Journal Of Gynecologic Cancer* 33, 1602–1611. <https://doi.org/10.1136/Ijgc-2023-004487>
- Chen, S., Zhang, L., Yan, G., Cheng, S., Fathy, A. H., Yan, N., & Zhao, Y., 2017, Neutrophil-To-Lymphocyte Ratio Is A Potential Prognostic Biomarker In Patients With Ovarian Cancer: A Meta-Analysis, *Biomed Research International* (Vol. 2017), Biomed Res Int. <https://doi.org/10.1155/2017/7943467>.
- Cristea, M., Han, E., Salmon, L., & Morgan, R. J., 2010, Review: Practical Considerations In Ovarian Cancer Chemotherapy. *Therapeutic Advances In Medical Oncology*, 2(3), 175–187. <https://doi.org/10.1177/1758834010361333>.
- Colombo, N., Sessa, C., Bois, A. Du, Ledermann, J., Mccluggage, W., Mcneish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F., Querleu, D., 2019. Esmo–Esgo Consensus Conference Recommendations On Ovarian Cancer: Pathology And Molecular Biology, Early And Advanced Stages, Borderline Tumours And Recurrent Disease. *International Journal Of Gynecologic Cancer* 29, 728–760. <https://doi.org/10.1136/Ijgc-2019-000308>
- Dahlan M.S. Besar Sampel Dalam Penelitian Kedokteran Dan Kesehatan. 2016. *Epidemiologi Indonesia*.
- Dahlan, S., 2016, *Statistik Untuk Kedokteran Dan Kesehatan Edisi 6*, Salemba Medika.
- Dao, F., Schlappe, B. A., Tseng, J., Lester, J., Nick, A. M., Lutgendorf, S. K., Mcmeekin, S., Coleman, R. L., Moore, K. N., Karlan, B. Y., Sood, A. K., & Levine, D. A., 2016, Characteristics Of 10-Year Survivors Of High-Grade Serous Ovarian Carcinoma, *Gynecologic Oncology*, 141(2), 260–263, <https://doi.org/10.1016/J.Ygyno.2016.03.010>.
- Elaskalani, O., Berndt, M. C., Falasca, M., & Metharom, P., 2017, Targetiapri, S., & Desi, Y. M. A., 2016, Faktor-Faktor Determinat Terjadinya Kanker Ovarium Di Rumah Sakit Umum Daerah Abdoel Mpelok Provinsi Lampung 2015, P- Issn: 2086-3071, E-Issn: 7(2), 79–87.
- Elinav, E. Et Al., 2013, ‘Inflammation-Induced Cancer: Crosstalk Between Tumours, Immune Cells And Microorganisms’, *Nature Reviews Cancer*, Springer Science And Business Media Llc, 13(11), Pp. 759–771, [Doi: 10.1038/Nrc3611](https://doi.org/10.1038/Nrc3611).
- Fauzan, R., 2009, Gambaran Faktor Penggunaan Kontrasepsi Terhadap Angka Kejadian Kanker Ovarium Di Rsupn Dr. Cipto Mangunkusumo Jakarta Berdasarkan Pemeriksaan Histopatologik Tahun 2003-2007, Fakultas Kedokteran Universitas Indonesia, 4–16.
- Gershenson, D.M., Sun, C.C., Bodurka, D., Coleman, R.L., Lu, K.H., Sood, A.K.,

- Deavers, M., Malpica, A.L., Kavanagh, J.J., 2009. Recurrent Low-Grade Serous Ovarian Carcinoma Is Relatively Chemoresistant. *Gynecol Oncol* 114, 48–52. <https://doi.org/10.1016/j.ygyno.2009.03.001>
- Gilks, C.B., Ionescu, D.N., Kalloger, S.E., Köbel, M., Irving, J., Clarke, B., Santos, J., Le, N., Moravan, V., Swenerton, K., 2008. Tumor Cell Type Can Be Reproducibly Diagnosed And Is Of Independent Prognostic Significance In Patients With Maximally Debulked Ovarian Carcinoma. *Hum Pathol* 39, 1239–1251.
- Gonzalez, H., Hagerling, C., Werb, Z., 2018. Roles Of The Immune System In Cancer: From Tumor Initiation To Metastatic Progression. *Genes Dev* 32, 1267–1284. <https://doi.org/10.1101/Gad.314617.118>
- Hoffman, 2016, Williams Gynecology 3rd Edition: Chapter 35 Epithelial Ovarian Cancer (3rd Ed.), McGraw Hill Education.
- Huang, Q. T., Zhou, L., Zeng, W. J., Ma, Q. Q., Wang, W., Zhong, M., & Yu, Y. H., 2017, Prognostic Significance Of Neutrophil-To-Lymphocyte Ratio In Ovarian Cancer: A Systematic Review And Meta-Analysis Of Observational Studies, *Cellular Physiology And Biochemistry*, 41(6), Pp. 2411–2418), Karger Publishers. <https://doi.org/10.1159/000475911>.
- Hosono, S., Kajiyama, H., Mizuno, K., Sakakibara, K., Matsuzawa, K., Takeda, A., Kawai, M., Nagasaka, T., Kikkawa, F., 2011. Comparison Between Serous And Non-Serous Ovarian Cancer As A Prognostic Factor In Advanced Epithelial Ovarian Carcinoma After Primary Debulking Surgery. *Int J Clin Oncol* 16, 524–532.
- Iarc, 2020, Indonesia-Global Cancer Observatory.
- Jeerakornpassawat D, Suprasert P. Potential Predictors For Chemotherapeutic Response And Prognosis In Epithelial Ovarian, Fallopian Tube And Primary Peritoneal Cancer Patients Treated With Platinum-Based Chemotherapy. *Obstet Gynecol Sci*. 2020 Jan;63(1):55–63. Doi: 10.5468/Ogs.2020.63.1.55. Epub 2019 Dec 23. Pmid: 31970128; Pmcid: Pmc6962588.
- Jones, C.I., 2016. Platelet Function And Ageing. *Mammalian Genome* 27, 358–366. <https://doi.org/10.1007/S00335-016-9629-8>
- Kim, Hee Seung, Hwa Young Choi, Maria Lee, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hyun Hoon Chung, Yong Beom Kim And Yong Sang Song. “Systemic Inflammatory Response Markers And Ca-125 Levels In Ovarian Clear Cell Carcinoma: A Two Center Cohort Study.” *Cancer Research And Treatment: Official Journal Of Korean Cancer Association* 48 (2015): 250 - 258.
- Kurman, R.J., Shih, I.-M., 2016. The Dualistic Model Of Ovarian Carcinogenesis. *Am J Pathol* 186, 733–747. <https://doi.org/10.1016/j.ajpath.2015.11.011>
- Kwon Bs, Jeong Dh, Byun Jm, Lee Th, Choi Ku, Song Yj, Suh Ds, Kim Kh. Prognostic Value Of Preoperative Lymphocyte-Monocyte Ratio In Patients With Ovarian Clear Cell Carcinoma. *J Cancer*. 2018 Mar 8;9(7):1127–1134. Doi: 10.7150/Jca.24057. Pmid: 29675093; Pmcid: Pmc5907660.
- Le Blanc, J., Lordkipanidzé, M., 2019. Platelet Function In Aging. *Front Cardiovasc Med* 6. <https://doi.org/10.3389/Fcvm.2019.00109>

- Lee, M., Chang, M. Y., Yoo, H., Lee, K. E., Chay, D. B., Cho, H., Kim, S., Kim, Y. T., & Kim, J. H. (2016). Clinical Significance Of Ca125 Level After The First Cycle Of Chemotherapy On Survival Of Patients With Advanced Ovarian Cancer. *Yonsei Medical Journal*, 57(3), 580-587.
- Li, L., Tian, J., Zhang, L., Liu, L., Sheng, C., Huang, Y., Zheng, H., Song, F., Chen, K., 2021. Utility Of Preoperative Inflammatory Markers To Distinguish Epithelial Ovarian Cancer From Benign Ovarian Masses. *J. Cancer* 12, 2687–2693. <https://doi.org/10.7150/Jca.51642>
- Lin, Y., Kim, J., Metter, E.J., Nguyen, H., Truong, T., Lustig, A., Ferrucci, L., Weng, N., 2016. Changes In Blood Lymphocyte Numbers With Age In Vivo And Their Association With The Levels Of Cytokines/Cytokine Receptors. *Immunity & Ageing* 13, 24. <https://doi.org/10.1186/S12979-016-0079-7>.
- Lusho, S., Durando, X., Mouret-Reynier, M. A., Kossai, M., Lacrampe, N., Molnar, I., Penault-Llorca, F., Radošević-Robin, N., & Abrial, C., 2021, Platelet-To-Lymphocyte Ratio Is Associated With Favorable Response To Neoadjuvant Chemotherapy In Triple Negative Breast Cancer: A Study On 120 Patients, *Frontiers In Oncology*, 11, 2764, <https://doi.org/10.3389/Fonc.2021.678315>.
- Miao, Y., Yan, Q., Li, S., Li, B., & Feng, Y., 2016, Neutrophil To Lymphocyte Ratio And Platelet To Lymphocyte Ratio Are Predictive Of Chemotherapeutic Response And Prognosis In Epithelial Ovarian Cancer Patients Treated With Platinum-Based Chemotherapy, *Cancer Biomarkers*, 17(1), 33–40, <https://doi.org/10.3233/Cbm-160614>.
- Nezhad, A. K., Ebrahimi, V., Ahmadpour, F., Momtahan, M., Robati, M., Saraf, Z., Ramzi, M., Jowkar, Z., & Ghaffari, P., 2020, Parity As A Prognostic Factor In Patients With Advanced-Stage Epithelial Ovarian Cancer, *Cancer Management And Research*, 12, 1447–1456.
- National Comprehensive Cancer Network. 2021. Nccn Guidelines For Patients Ovarian Cancer. 3025 Chemical Rd Suite 100, Plymouth Meeting, Pa 19462, Amerika Serikat
- Rkbr., 2018, Registrasi Kanker Berbasis Rumah Sakit Dr Sardjito/Fkkmk Ugm. <http://canreg.fk.ugm.ac.id/laporan-data/rkbr-oktober-2018/>.
- Raunkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet To Lymphocyte Ratio As A Prognostic Factor For Epithelial Ovarian Cancer. *J Gynecol Oncol*. 2012 Oct;23(4):265-73. Doi: 10.3802/Jgo.2012.23.4.265. Epub 2012 Sep 19. Pmid: 23094130; Pmcid: Pmc3469862.
- Ramón-Rodríguez J, De-Armas-Conde N, Jaén-Torrejimeno I, Prada-Villaverde A, Rojas-Holguín A, López-Guerra D, Blanco-Fernández G. Prognostic Value Of Pre-Operative Systemic Immune-Inflammation Index And Platelet To Lymphocyte Ratio In Peritoneal Carcinomatosis Of Ovarian Origin. *Surg Oncol*. 2022 Jun;42:101750. Doi: 10.1016/J.Suronc.2022.101750. Epub 2022 Mar 30. Pmid: 35378377.
- Rustin, G.J.S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., Du Bois, A., Kristensen, G., Jakobsen, A., Sagae, S., Greven, K., Parmar, M., Friedlander, M., Cervantes, A., Vermorken, J., 2011. Definitions

- For Response And Progression In Ovarian Cancer Clinical Trials Incorporating Recist 1.1 And Ca 125 Agreed By The Gynecological Cancer Intergroup (Gcig). *International Journal Of Gynecologic Cancer* 21, 419–423. <https://doi.org/10.1097/igc.0b013e3182070f17>
- Salima, S., 2016. Korelasi Antara Ekspresi Tumor Infiltrating Lymphocytes Cd4 Dan Cd8 Dengan Kanker Ovarium Tipe Epitel Stadium Lanjut Yang Bebas Penyakit Dan Kekambuhan. *Indonesian Journal Of Cancer* 10, 43. <https://doi.org/10.33371/ijoc.v10i2.424>
- Santoemma, P. P., & Powell, D. J., 2015, Tumor Infiltrating Lymphocytes In Ovarian Cancer, *Cancer Biology And Therapy*, 16(6), 807–820, <https://doi.org/10.1080/15384047.2015.1040960>.
- Savant, S.S., Sriramkumar, S., & O'hagan, H.M., 2018. The Role Of Inflammation And Inflammatory Mediators In The Development, Progression, Metastasis, And Chemoresistance Of Epithelial Ovarian Cancer. *Cancers (Basel)*. 10. [Doi:10.3390/Cancers10080251](https://doi.org/10.3390/Cancers10080251)
- Siswosudarmo, R. Pendekatan Praktis Penelitian Epidemiologi Klinis Dan Aplikasi Spss Untuk Analisis Statistika. Bagian Obstetrika Dan Ginekologi Fakultas Kedokteran Universitas Gadjah Mada, Yogyakarta. 2015
- Sjoquist, K. M., Lord, S. J., Friedlander, M. L., John Simes, R., Marschner, I. C., & Lee, C. K., 2018, Progression-Free Survival As A Surrogate Endpoint For Overall Survival In Modern Ovarian Cancer Trials: A Meta-Analysis, *Therapeutic Advances In Medical Oncology*, 10, <https://doi.org/10.1177/1758835918788500>.
- Song W, Tian C, Wang K, Zhang Rj, Zou Sb. Preoperative Platelet Lymphocyte Ratio As Independent Predictors Of Prognosis In Pancreatic Cancer: A Systematic Review And Meta-Analysis. *Plos One*. 2017 Jun 2;12(6):E0178762. [Doi: 10.1371/journal.pone.0178762](https://doi.org/10.1371/journal.pone.0178762). [Pmid: 28575033](https://pubmed.ncbi.nlm.nih.gov/28575033/); [Pmcid: Pmc5456351](https://pubmed.ncbi.nlm.nih.gov/28575033/).
- Song Q, Xu Sx, Wu Jz, Ling L, Wang S, Shu Xh, Ying Dn, Pei Ww, Wu Yc, Sun Sf, Zhang Yn, Zhou Sh, Shao Zy. The Preoperative Platelet To Neutrophil Ratio And Lymphocyte To Monocyte Ratio Are Superior Prognostic Indicators Compared With Other Inflammatory Biomarkers In Ovarian Cancer. *Front Immunol*. 2023 Jun 30;14:1177403. [Doi: 10.3389/fimmu.2023.1177403](https://doi.org/10.3389/fimmu.2023.1177403). [Pmid: 37457691](https://pubmed.ncbi.nlm.nih.gov/37457691/); [Pmcid: Pmc10347525](https://pubmed.ncbi.nlm.nih.gov/37457691/).
- Supoken A, Kleeckaow P, Chumworathayi B, Luanratanakorn S, Kietpeerakool C. Elevated Preoperative Platelet To Lymphocyte Ratio Associated With Decreased Survival Of Women With Ovarian Clear Cell Carcinoma. *Asian Pac J Cancer Prev*. 2014;15(24):10831-6. [Doi: 10.7314/apjcp.2014.15.24.10831](https://doi.org/10.7314/apjcp.2014.15.24.10831). [Pmid: 25605185](https://pubmed.ncbi.nlm.nih.gov/25605185/).
- Tian C, Song W, Tian X, Sun Y. Prognostic Significance Of Platelet-To-Lymphocyte Ratio In Patients With Ovarian Cancer: A Meta-Analysis. *Eur J Clin Invest*. 2018 May;48(5):E12917. [Doi: 10.1111/Eci.12917](https://doi.org/10.1111/Eci.12917). [Epub 2018 Mar 24. Pmid: 29469190](https://pubmed.ncbi.nlm.nih.gov/29469190/).
- Van Zyl B, Tang D, Bowden Na. Biomarkers Of Platinum Resistance In Ovarian Cancer: What Can We Use To Improve Treatment. *Endocr Relat Cancer*.

- 2018 May;25(5):R303-R318. Doi: 10.1530/Erc-17-0336. Epub 2018 Feb 27. Pmid: 29487129.
- Van Zyl, B., Tang, D., Bowden, N.A., 2018. Biomarkers Of Platinum Resistance In Ovarian Cancer: What Can We Use To Improve Treatment. *Endocr Relat Cancer* 25, R303–R318. <https://doi.org/10.1530/Erc-17-0336>
- Weng, N., 2006. Aging Of The Immune System: How Much Can The Adaptive Immune System Adapt? *Immunity* 24, 495–499. <https://doi.org/10.1016/j.immuni.2006.05.001>
- Winarno, G., Pasaribu, M., Susanto, H., Nisa, A., Harsono, A., Yuseran, H., Suardi, D., Trianasari, N., 2021. The Platelet To Lymphocyte And Neutrophil To Lymphocyte Ratios In Predicting Response To Platinum-Based Chemotherapy For Epithelial Ovarian Cancer. *Asian Pacific Journal Of Cancer Prevention* 22, 1561-1566.
- Winata, J., Laihad, B.J., Wagey, F.M.M., 2023. Preoperative Platelet-Lymphocyte Ratio As A Prognostic Factor Of Epithelial Ovarian Cancer. *Indonesian Journal Of Obstetrics And Gynecology*. <https://doi.org/10.32771/inajog.v11i1.1738>
- Winter, W.E., Maxwell, G.L., Tian, C., Sundborg, M.J., Rose, G.S., Rose, P.G., Rubin, S.C., Muggia, F., McGuire, W.P., 2008. Tumor Residual After Surgical Cytoreduction In Prediction Of Clinical Outcome In Stage Iv Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. *Journal Of Clinical Oncology* 26, 83–89. <https://doi.org/10.1200/Jco.2007.13.1953>
- Xiang, J., Zhou, L., Li, X., Bao, W., Chen, T., Xi, X., He, Y., & Wan, X., 2017, Preoperative Monocyte-To-Lymphocyte Ratio In Peripheral Blood Predicts Stages, Metastasis, And Histological Grades In Patients With Ovarian Cancer, *Translational Oncology*, 10(1), 33–39, <https://doi.org/10.1016/j.tranon.2016.10.006>.
- Yang, L., Xie, H.-J., Li, Y.-Y., Wang, X., Liu, X.-X., Mai, J., 2022. Molecular Mechanisms Of Platinum Based Chemotherapy Resistance In Ovarian Cancer (Review). *Oncol Rep* 47, 82. <https://doi.org/10.3892/or.2022.8293>
- Ye, S., Chen, W., Zheng, Y., Wu, Y., Xiang, L., Li, T., Ping, B., Zhang, X., & Yang, H. (2022). Peripheral Lymphocyte Populations In Ovarian Cancer Patients And Correlations With Clinicopathological Features. *Journal Of Ovarian Research*, 15(1). <https://doi.org/10.1186/s13048-022-00977-3>
- Yildirim, M., Demir Cendek, B., & Filiz Avzar, A., 2015, Differentiation Between Benign And Malignant Ovarian Masses In The Preoperative Period Using Neutrophil-To-Lymphocyte And Platelet-To-Lymphocyte Ratios, *Molecular And Clinical Oncology*, 3(2), 317–321, <https://doi.org/10.3892/mco.2014.481>.
- Yu, L., Guo, Y., Chang, Z., Zhang, D., Zhang, S., Pei, H., Pang, J., Zhao, Z.J., Chen, Y., 2021. Bidirectional Interaction Between Cancer Cells And Platelets Provides Potential Strategies For Cancer Therapies. *Front Oncol* 11. <https://doi.org/10.3389/fonc.2021.764119>
- Zayyan, M.S. Risk Factors For Ovarian Cancer. *Tumor Progression And Metastasis*. 2020

- Zhang Cl, Jiang Xc, Li Y, Pan X, Gao Mq, Chen Y, Pang B. Independent Predictive Value Of Blood Inflammatory Composite Markers In Ovarian Cancer: Recent Clinical Evidence And Perspective Focusing On Nlr And Plr. *J Ovarian Res.* 2023 Feb 9;16(1):36. Doi: 10.1186/S13048-023-01116-2. Pmid: 36759864; Pmcid: Pmc9912515.
- Zhang J, Yu Kf. What's The Relative Risk? A Method Of Correcting The Odds Ratio In Cohort Studies Of Common Outcomes. *Jama.* 1998;280(19):1690–1691. Doi:10.1001/Jama.280.19.1690
- Zhou, J., Wu, S.-G., Wang, J., Sun, J.-Y., He, Z.-Y., Jin, X., Zhang, W.-W., 2018. The Effect Of Histological Subtypes On Outcomes Of Stage Iv Epithelial Ovarian Cancer. *Front Oncol* 8. <https://doi.org/10.3389/Fonc.2018.00577>
- Van Zyl, B., Tang, D., Bowden, N.A., 2018. Biomarkers Of Platinum Resistance In Ovarian Cancer: What Can We Use To Improve Treatment. *Endocr Relat Cancer* 25, R303–R318. <https://doi.org/10.1530/Erc-17-0336>.